Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma.
- Author:
Young Il KIM
1
;
Hee Chul PARK
;
Do Hoon LIM
;
Hyo Jung PARK
;
Sang Won KANG
;
Su Yeon PARK
;
Jin Sung KIM
;
Youngyih HAN
;
Seung Woon PAIK
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. rophc@skku.edu
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Hepatocellular carcinoma
- MeSH:
Carcinoma, Hepatocellular;
Follow-Up Studies;
Humans;
Liver;
Retrospective Studies
- From:Radiation Oncology Journal
2012;30(4):189-196
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate the safety of high dose hypofractionated radiotherapy (RT) in patients with small hepatocellular carcinoma (HCC) in terms of liver volumetric changes and clinical liver function. MATERIALS AND METHODS: We retrospectively reviewed 16 patients with small HCC who were treated with high dose hypofractionated RT between 2006 and 2009. The serial changes of the liver volumetric parameter were analyzed from pre-RT and follow-up (FU) computed tomography (CT) scans. We estimated linear time trends of whole liver volume using a linear mixed model. The serial changes of the Child-Pugh (CP) scores were also analyzed in relation to the volumetric changes. RESULTS: Mean pre-RT volume of entire liver was 1,192.2 mL (range, 502.6 to 1,310.2 mL) and mean clinical target volume was 14.7 mL (range, 1.56 to 70.07 mL). Fourteen (87.5%) patients had 4 FU CT sets and 2 (12.5%) patients had 3 FU CT sets. Mean interval between FU CT acquisition was 2.5 months. After considering age, gender and the irradiated liver volume as a fixed effects, the mixed model analysis confirmed that the change in liver volume is not significant throughout the time course of FU periods. Majority of patients had a CP score change less than 2 except in 1 patient who had CP score change more than 3. CONCLUSION: The high dose hypofractionated RT for small HCC is relatively safe and feasible in terms of liver volumetric changes and clinical liver function.
